Our Q1 2020 report includes our first ever historical price and patient dose analysis combining data from our previous publications to show long-term market trends.
Our Q3 2019 report is the most comprehensive review of the marketplace to date, the product of two-and-a-half years constantly and cumulatively tracking data.
Our Q1 2019 report gives insight for the first time into new metrics around product floor prices, revenue forecasts and market size.
Our analysis has revealed that over the past 12 months, there has been a significant increase in the number, and variety of legal products on offer to Australian patients.